DARA Biosciences Inc

DARA Biosciences — IPO Roadshow (October 2008)

32 slides from DARA Biosciences's IPO roadshow presentation, Oct 29, 2008

  1. Slide 1: 7th Annual BIO Investor Forum

    Filed Pursuant to Rule 433 Registration No. 333-150150 October 30, 2008 th 7 Annual BIO Investor Forum October 30, 2008 Confidential 1

  2. Slide 2: “A good presentation is like a dress; long enough to cover everything and short

    “A good presentation is like a dress; long enough to cover everything and short enough to keep your interest.” Edith Vanderbilt Confidential 2

  3. Slide 3: Registration Statement; SEC Filings; Sources

    Registration Statement; SEC Filings; Sources The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has f

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements Confidential 4

  5. Slide 5: We are…

    We are… Developing drugs that address large market opportunities Product focused, no discovery research Reducing product development risk Five diverse drug development programs targeting multiple high- value therapies Opportunistic Balance of proven and innovative mechanisms of action Focused on low

  6. Slide 6: Investment Consideration

    Investment Consideration High value drug development programs Attractive development partner for big Pharma 9.7 % ownership in SurgiVision, 31% voting rights Potential for 2009 revenue Risk adverse strategy Confidential 6

  7. Slide 7: Corporate Strategy

    Corporate Strategy Acquisition, Development and Sale Drug Marketing Discovery Approval Discovery Pre-Clinical IND Phase I Phase II Phase III Research DARA HIGHEST FOCUS HIGHEST RISK $$$ Confidential 7

  8. Slide 8: Earlier Phase Deals Yielding Higher Value Terms

    Earlier Phase Deals Yielding Higher Value Terms Change in Cost of Deal Terms 2003 by Clinical Phase of Asset* 2006 400 Value of Phase 1 350 365 and 2 development 300 250 280 300 deals have 200 increased by 75% 190 171 150 160 100 50 0 Phase I Phase II Phase III *SOURCE: Jones, A. Minimizing Leakage

  9. Slide 9: Current Pipeline

    Current Pipeline Candidate Selection Lead Proof of Pre-Clinical Indication Drug Identification Principle Development Phase 1 Phase 2a Neuropathic Pain KRN5500 First in Class – No Competition for Drugs of its Type Type 2 Diabetes DB959 Leader in its Class – No Competition in the Clinic Type 2 Diabete

  10. Slide 10: Cancer Neuropathic Pain: KRN5500

    Cancer Neuropathic Pain: KRN5500 Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Active component of KRN5500 has been shown to inhibit nerve cell pain signals 30% of Cancer patients have neuropathic pain 38% of Cancer patients on poly-chemotherapy

  11. Slide 11: KRN5500 Phase 2 Trials

    KRN5500 Phase 2 Trials Current Phase 2a trial: Terminally-ill cancer patients who have failed 2 treatments for their neuropathic pain Randomized, double-blind, placebo controlled study in 18 patients over 14-week duration Dose escalation scheme; 4 dose levels Study completion expected in 4Q08 Next P

  12. Slide 12: KRN5500 Non-Clinical Studies

    KRN5500 Non-Clinical Studies Effective in 3 different models of Neuropathic Pain SNI Model Chung Model Bennett Model Ineffective in a model of Regular (nociceptive) Pain CFA Model References: Kobierski, L.A., et.al, Anesth Analg 2003;97:174 –82 Abdi, S., et.al., Anesth Analg 2000;91:955–9 Confidenti

  13. Slide 13: Type 2 Diabetes: DB959 (PPAR Agonist)

    Type 2 Diabetes: DB959 (PPAR Agonist) (delta/gamma) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Activates genes involved in metabolism of sugars and fats, improving the body’s ability to regulate blood sugar Novel combination of PPAR activitie

  14. Slide 14: PPAR-Delta in the News

    PPAR-Delta in the News Confidential 14

  15. Slide 15: PPAR-Delta in the News

    PPAR-Delta in the News PPAR-delta compound GW-501516 increases endurance 75% Boosts the production of muscle fibers which burn fat rather than sugar for energy - “Exercise in a pill” DB959 is a delta compound like GW-501516 but with the added benefit of gamma activity to treat high blood sugar in di

  16. Slide 16: DB959 is a Potent Stimulator of Fatty Acid Oxidation

    DB959 is a Potent Stimulator of Fatty Acid Oxidation (‘fat burning’) in C2C12 Skeletal Muscle Cells DB959 is more potent than GW-501516 200 DB959 150 GW501516 100 Rosiglitazone 50 0 -10 -9 -8 -7 -6 -5 -4 -3 Log [Compound], M Confidential 16

  17. Slide 17: Is There a Future for PPARs?

    Is There a Future for PPARs? Patient Value: 1. Reduces Insulin Resistance 2. Lowers Blood Sugar 3. Reduces Ectopic Fat Accumulation in the Liver 4. Delays the Onset of Type 2 Diabetes Market Value: 2 nd largest sales and market share next to insulins [Ref: Datamonitor Pipeline Insight Non-Insuline A

  18. Slide 18: Improvements are Needed

    Improvements are Needed Avandia® and Actos® Positive Negative 1. Reduces Insulin Resistance 1. Increased Risk of MI Events? 2. Lowers Blood Sugar 2. Weight Gain 3. Reduces Ectopic Fat Accumulation in the Liver 4. Delays the Onset of Type 2 Diabetes DB959 Potential Positives 1. Reduces Insulin Resist

  19. Slide 19: Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia

    Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia® ® Avandia Dose Cardiac Effect @ 3 times human exposure* 20% increase in Heart Weight in all females @ 42 times human exposure* 28% increase in Heart Weight in all females 32% Increase in Heart Weight in all males Avandia: Toxicology s

  20. Slide 20: Non-Clinical Studies Suggest Less Weight Gain than Avandia

    Non-Clinical Studies Suggest Less Weight Gain than Avandia® Effects of chronic treatment with DB959, rosiglitazone, and muraglitazar on body weight in DIO mice PEG/H2O 15 DB959 @ 100mg/kg * 14 Muraglitizar @ 10mg/kg 13 * Rosiglitazone @ 10mg/kg 12 * * * 11 * * 10 * * 9 * * * * * * 8 * * * 7 * * * *

  21. Slide 21: DB959 Non-Clinical Activity

    DB959 Non-Clinical Activity Leading successor to Avandia ® and Actos® (whose combined 2006 sales were > $5.6 billion) Glucose control equal to or better than Avandia Lowers Triglycerides better than Avandia Increases good HDL cholesterol better than Avandia Improves HDL: LDL ratio better than Avandi

  22. Slide 22: DB959 and DB900 vs. Avandia and Actos

    DB959 and DB900 vs. Avandia and Actos DB959 DB900 Avandia Actos Glucose Control Increase HDL Lower Triglycerides Lower LDL Lower Total Cholesterol Weight Control Confidential 22

  23. Slide 23: Psoriasis: DB200 (Topical)

    Psoriasis: DB200 (Topical) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Inhibits the proliferation of skin cells by cutting off their energy source - resulting in less flaking of the skin and restoration of normal skin tone Inhibits inflammatio

  24. Slide 24: The Promise of DB200 for Psoriasis

    The Promise of DB200 for Psoriasis No other drug in its class New topical therapies in development only address inflammation (e.g. PMX-53, PTH1-34, AN-2728) DB200 reduces both inflammation and skin cell growth Once a day topical therapy (>76% of treated patients are on a topical therapy) Safer and m

  25. Slide 25: Current Pipeline

    Current Pipeline Candidate Selection Lead Proof of Pre-Clinical Indication Drug Identification Principle Development Phase 1 Phase 2a Neuropathic Pain KRN5500 First in Class – No Competition for Drugs of its Type Type 2 Diabetes DB959 Leader in its Class – No Competition in the Clinic Type 2 Diabete

  26. Slide 26: DARA – Potential for Value Creation

    DARA – Potential for Value Creation Key Assets: 5 therapeutic compounds with strong IP addressing large markets MiMedX (MDXG.OB): Development stage company, focusing on products primarily used by musculoskeletal specialists in surgical and non-surgical therapy. DARA owns ~ 400,000 shares. SurgiVisio

  27. Slide 27: Creating Shareholder Value

    Creating Shareholder Value Compound Out-Licensing Compound In-Licensing Maximize value of minority equity position Confidential 27

  28. Slide 28: SurgiVision’s mission

    SurgiVision’s mission is to develop and commercialize Real-Time, MRI-Guided Therapeutic Systems to improve patients’ quality of life by harnessing the power of magnetic resonance imaging to drive the next generation of minimally invasive surgical procedures. With SurgiVision’s Systems, surgeons… GUI

  29. Slide 29: SurgiVision offices, IP and anticipated launch

    Offices in Irvine, Baltimore, and Memphis – 17 employees Extensive intellectual property portfolio covering MRI-Guided Therapeutic interventions Sponsored research relationships with UC San Francisco (neuro) and Univ of Utah (cardiac) License agreements with Boston Scientific in the fields of implan

  30. Slide 30: Steve Gorlin, Thomas W. D’Alonzo, John Didsbury

    Nationally featured in renowned publications, such as The Wall Street Journal and Fortune Magazine, as an authority in the healthcare industry Founder and Co-Chairman Founder of several highly successful biotechnology and pharmaceutical companies Steve Gorlin of the Board including Medicis Pharmaceu

  31. Slide 31: Board Directors

    Chairman, Tranzyme, Inc. and Tranzyme Pharma Inc. Director, MethylGene Inc. (TSX:MYG) Former VP, Clinical Development; Daiichi Pharmaceutical Corporation David J. Drutz, M.D. Board Director Former VP, Biological Sciences and VP, Clinical Investigation, Smith Kline & French Laboratories Former Presid

  32. Slide 32: Summary

    Summary Clearly defined business strategy addressing large pharma pipeline gaps Diverse portfolio of programs targeting multi-billion dollar market segments Limited reliance on a single drug candidate or therapeutic category Pursuing both proven and innovative mechanisms Lower risk / lower cost appr

DARA BioSciences — IPO Roadshow (October 2008) on 6ix